HSD17B13 and hepatocellular carcinoma: In this meta-analysis, we found that the HSD17B13 rs72613567:TA allelic variant can decrease the risk of HCC in CLD (TA vs T OR = 0.766, 95% CI = 0.682–0.860, P = 0.000; TATA + TAT vs TT OR = 0.755, 95% CI = 0.645–0.885, P = 0.001) or healthy controls(TA vs T OR = 0.649, 95% CI = 0.431–0.977, P = 0.038).